Shilpa Medicare’s joint venture Oncosol, with Shorla Oncology, has gained US FDA approval for IMKELDI, an imatinib oral ...

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing ...

Imatinib oral solution has gained FDA approval for the treatment of some cancers, including certain forms of leukemia.

Kura Oncology Inc. (KURA) said that it has entered into a global strategic collaboration with Kyowa Kirin Co., Ltd. to develop and ...

Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in ...

DelveInsight’s “Gastrointestinal Stromal Tumor Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Gastrointestinal Stromal Tumor, historical and ...

A man who has incurable cancer has begun a new career in teaching. Chris Johnson, from Sunderland, was diagnosed with a ...

Gastrointestinal stromal tumours (GISTs) are clinically heterogeneous, with varying degrees of aggressiveness. Here, the authors describe the genomic and transcriptomic landscape of 117 GISTs from ...

Blueprint Medicines' AYVAKIT leads its revenue growth, while its pipeline targets multiple cancers. Read why BPMC stock is a ...

Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The Lancet Oncology – – Data from 100 patients in Phase 1a do ...

Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models – – Proof-of-concept study of ziftomenib plus ...